The Big Pharma has the global scale and reach it needs, but will fill in gaps with deals in which it can add “a lot of” scientific value and “incremental” commercial value, says Pfizer’s EVP-Business Development Kristin Peck.

Pfizer takes a middle-of-the-road approach to breaking out non-core businesses, announcing plans to explore alternatives for Animal Health and Nutrition.

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.